

DIASORIN SIGNS STRATEGIC DISTRIBUTION AGREEMENT WITH MCKESSON MEDICAL SURGICAL TO EXPAND ACCESS FOR THE LIAISON NES MOLECULAR POINT-OF-CARE PLATFORM AND THE FLU A/B, RSV & COVID-19 PANEL IN NON-ACUTE SETTINGS ACROSS THE UNITED STATES

- DIASORIN SIGNS AN EXCLUSIVE DISTRIBUTION AGREEMENT WITH MCKESSON MEDICAL SURGICAL, A DIVERSIFIED HEALTHCARE SERVICES COMPANY WITH A MARKET-LEADING POSITION IN NON-ACUTE CARE;
- THE LIAISON NES ENABLES RAPID, LAB-QUALITY MOLECULAR DIAGNOSTICS IN NEAR-PATIENT SETTINGS, DELIVERING RESULTS IN ~15 MINUTES WITH A SIMPLE THREE-STEP WORKFLOW;
- WITH THIS SECOND DISTRIBUTION AGREEMENT, DIASORIN HAS ACHIEVED COVERAGE OF BOTH THE ACUTE HOSPITAL AND IDNs AND NON-ACUTE PHYSICIAN OFFICE LAB (POL) SEGMENTS.

Saluggia, Italy – March 19, 2026 - Diasorin (FTSE MIB: DIA) announced today a strategic distribution agreement with the distributor McKesson Medical Surgical to accelerate and support the commercialization of the LIAISON NES molecular point-of-care solution across physician offices, urgent care centers, and other decentralized testing locations in the United States.

The agreement is specifically aimed at penetrating the non-acute segment, where McKesson Medical Surgical holds a market-leading position through its extensive reach, logistics capabilities, and long-standing relationships with community-based healthcare providers. Through this agreement, McKesson Medical Surgical will support the commercialization of the LIAISON NES platform and its first FDA-cleared assay, the Flu A/B, RSV & COVID-19 Panel, enabling broader access to high-quality molecular diagnostics outside the traditional hospital laboratory.

The U.S. non-acute market represents a significant growth opportunity for molecular diagnostics, with more than 130,000 physician office laboratories and decentralized testing sites performing respiratory testing each year. McKesson Medical Surgical's leadership in this segment, combined with its nationwide distribution infrastructure and deep customer relationships, positions the company as a strategic distribution service provider to scale the LIAISON NES platform and support Diasorin's long-term expansion in decentralized care.

"The distribution agreement with McKesson Medical Surgical represents a key milestone in our strategy to expand molecular point-of-care testing beyond the hospital and into the settings where most patient interactions occur," said Carlo Rosa, CEO of Diasorin. *"LIAISON NES was specifically designed to meet the needs of non-acute environments, and McKesson Medical Surgical's leadership in this segment will allow us to accelerate adoption and bring high-quality molecular diagnostics closer to patients."*

The agreement complements Diasorin's existing U.S. commercial organization and the recently announced distribution agreement with another industry player, aimed to accelerate penetration into the hospital segment and to support access to major U.S. Integrated Delivery Networks (IDNs), while reinforcing the Company's commitment to building a comprehensive go-to-market model across decentralized healthcare settings.

Diasorin continues to invest in the expansion of its molecular portfolio for the LIAISON NES platform, with additional assays in development to further support the needs of non-acute care providers.



About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo

Corporate Investor Relations & ESG Senior Analyst
eugenia.ragazzo@diasorin.com